# Sonoma Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sonoma-biotherapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.sonomabio.com
- Total disclosed funding: $335M
- Latest round: Series B (Jul 26, 2021)
- Investors on record: 24

## About

Based in California, US, and founded in 2020, Sonoma Biotherapeutics, Inc. develops adoptive Treg therapies cell for autoimmune and inflammatory diseases. The company was co-founded by Alexander Rudensky, Fred Ramsdell, Jeffrey Bluestone (CEO), and Qizhi Tang. As of August 2021, the company raised a total funding of USD 335 million from investors including Mirae Asset Venture Investment, Ally Bridge Group, Casdin Capital, and Deep Track Capital.

The company's programs include SBT-77-7101, a novel CAR-based Treg cell therapy for patients with refractory rheumatoid arthritis, SBT-11-5301, a Teff conditioning biologic designed to help clear the inflammatory environment and make Treg cell therapies effective, and SBT-77-7200 Series for other autoimmune and inflammatory diseases.

The company plans to advance its Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune, and inflammatory diseases, and to further invest in and further enhance its manufacturing operations in order to support supply for initial clinical studies.

## Funding rounds

- Series B, Jul 26, 2021, $265M — ARCH Venture Partners, Frazier Healthcare Partners, Alexandria Venture Investments, OUP (Osage University Partners), Piper Sandler, Lilly Asia Ventures, Fidelity Investments, GV, ArrowMark Partners, Casdin Capital, Ally Bridge Group, Mirae Asset Venture Investment, 8VC, Vertex Ventures HC, JDRF T1D Fund, LifeForce Capital, Timefolio Capital, Janus Henderson Investors, Avidity Partners, Octagon Capital, Deep Track Capital
- Series A, Sep 30, 2020, $30M — ARCH Venture Partners, Lilly Ventures, Alexandria Venture Investments, 8VC, JDRF T1D Fund, LifeForce Capital, Lyell Immunopharma, Inc., Octagon Capital
- Series A, Feb 6, 2020, $40M — ARCH Venture Partners, 8VC, Milky Way Ventures, Lyell Immunopharma, Inc.

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A, Series B
- Milky Way Ventures (https://capitalatlas.ai/funds/milky-way-ventures) — Series A
- Lyell Immunopharma, Inc. — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A, Series B
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series A, Series B
- Octagon Capital — Series A, Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- ArrowMark Partners — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series B
- Timefolio Capital — Series B
- Janus Henderson Investors — Series B
- Avidity Partners — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B